therapy for patients with BCG-unresponsive nonmuscle-invasive bladder cancer (NMIBC) (1 Trusted Source Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with ...

Exploratory outcome measures include health-related quality of life, overall survival, and biomarker assessments. A broad cross-section of geographically and socioeconomically diverse clinical sites ...

Due to the ongoing shortage of BCG, gemcitabine has been increasingly used for first-line NMIBC therapy. N-803’s ability to activate natural killer and CD8+ T cells, thus the innate immune system, to ...

First real-world outcomes data for ADSTILADRIN® (nadofaragene firadenovec-vncg) to be presented at 2025 ASCO Genitourinary ...

Bladder cancer can be curable, and the likelihood of cure is higher if it is diagnosed at an early stage. Without treatment, bladder cancer does not go away on its own, and treatment is associated ...

In patients with stage pT1 urothelial bladder cancer, intravesical bacillus Calmette-Guérin (TheraCys, TICE BCG) combined with electromotive mitomycin-C produces higher remission rates and longer ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

How does the cost-effectiveness of treatments, particularly in relation to newer therapies, influence your recommendations for patients with BCG-unresponsive NMIBC? Are there specific tools or ...

The Boston Consulting Group (BCG) is ranked among the most prestigious consulting firms to work for. One of the renowned Big Three consultancies, BCG is also a major recruiter of MBA and business ...